Abstract: A transdermal therapeutic system (TTS) for administering at least one partial dopamine D2 agonist, comprising an active substance-impermeable backing layer, an active substance reservoir and a detachable protective layer, where the active substance reservoir is pressure-sensitive adhesive or the TTS is provided with at least one pressure-sensitive adhesive layer, and where the active substance reservoir is configured as a matrix system or as a membrane system, is characterized in that the active substance reservoir contains at least one active substance from the group of partial dopamine D2 agonists.

Abstract: A transdermal therapeutic system in the form of a patch for administration of the active agent venlafaxine comprises an active agent-impermeable backing layer, an active substance reservoir connected therewith and containing the active agent venlafaxine, a pressure-sensitive adhesive layer on the skin side, and an active agent-impermeable protective layer detachable prior to application.

Abstract: A lerisetron pharmaceutical preparation in the form of a transdermal therapeutic system (TTS) comprises a backing layer, connected to it an at least single-layer pressure-sensitively adhesive, lerisetron active substance reservoir based on silicone pressure-sensitive adhesive(s), and a removable protective layer.

Abstract: A zaleplon-containing pharmaceutical preparation is a transdermal therapeutic system in plaster form, having a backing layer, having a contact adhesive active ingredient reservoir connected thereto, and having a protective layer which can be detached before application, where the active ingredient reservoir comprises zaleplon.